Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.
Arnulf H Koeppen
https://pubmed.ncbi.nlm.nih.gov/21315377/Actively Recruiting
Led by Larimar Therapeutics, Inc. · Updated on 2026-10-27
85
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are studying Friedreichs ataxia FRDA, a condition affecting children aged 2 years and older, adolescents, and adults up to 60 years old. This open-label study evaluates the long-term safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and clinical effects of CTI-1601, a recombinant fusion protein designed to deliver the deficient human frataxin protein in FRDA patients. The study enrolls both patients who have and have not participated in prior CTI-1601 trials. Participants receive daily subcutaneous injections of CTI-1601. Those aged 18 years and older receive a fixed dose of 50 mg, while children and adolescents aged 2 to 17 years receive a weight-based dose of 0.8 mgkg up to a maximum of 50 mg. The treatment period lasts up to 24 months, during which safety, clinical, and biological effects are monitored closely. During the study, participants undergo regular assessments including monitoring of adverse events, heart function via electrocardiograms and echocardiograms, and neurological and motor function tests such as the modified Friedreichs Ataxia Rating Scale mFARS, 9-hole peg test, and timed 25-foot walk. Tissue frataxin levels are measured through cheek swabs and skin biopsies. Patient and clinician global impressions of change, activities of daily living, fatigue, and gene expression are also evaluated. Pharmacokinetic sampling occurs at multiple time points throughout the study to analyze drug exposure. The study lasts up to 24 months, with ongoing safety and clinical monitoring.
CONDITIONS
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
L
Larimar Therapeutics, Inc.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Larimar Therapeutics, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CTI‑1601 (nomlabofusp) | Omaveloxolone (Skyclarys) |
|---|---|---|
| What it is | An investigational recombinant fusion protein delivering human frataxin via subcutaneous injection | An approved oral drug (Nrf2 activator) used to modify disease progression in FRDA |
| Role in study | Single‑arm investigational treatment being evaluated for safety, pharmacokinetics, frataxin levels and clinical outcomes | Current disease‑modifying therapy available outside the trial |
| Primary use | To replace deficient frataxin in FRDA by delivering functional protein to mitochondria | To activate Nrf2‑related pathways and support mitochondrial function to slow FRDA progression |
| How it is given or performed | Subcutaneous injection of fusion protein, daily administration | Oral daily tablet taken by mouth |
| Evidence status | Early‑phase evidence shows safety, pharmacokinetics, and increased frataxin in tissues; efficacy outcomes not yet established | Clinical data support benefits on neurological measures and progression slowing |
| Important risks | Safety profile based on short‑term data with generally mild adverse events and no serious adverse events reported | Associated with elevated liver enzymes, GI symptoms, fatigue and requires monitoring of liver function |
| Important limitations | Results are from an open‑label, single‑arm study without established efficacy data and long‑term outcomes | Effectiveness may vary and benefits may be modest; long‑term impact still under evaluation |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants receive daily subcutaneous injections of CTI-1601 with doses based on age and weight. Safety, motor function, neurological status, and frataxin protein levels are regularly monitored.
Multiple visits for assessments and blood sampling at scheduled intervals
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Arnulf H Koeppen
https://pubmed.ncbi.nlm.nih.gov/21315377/Michael Lazaropoulos, Yina Dong, Elisia Clark...
https://pubmed.ncbi.nlm.nih.gov/26339677/R Rudick, J Antel, C Confavreux...
https://pubmed.ncbi.nlm.nih.gov/8797541/J D Fisk, P G Ritvo, L Ross...
https://pubmed.ncbi.nlm.nih.gov/8148458/D E Goodkin, D Hertsgaard, J Seminary
https://pubmed.ncbi.nlm.nih.gov/3178453/Eric C Deutsch, Avni B Santani, Susan L Perlman...
https://pubmed.ncbi.nlm.nih.gov/20675166/Massimo Pandolfo
https://pubmed.ncbi.nlm.nih.gov/18852343/M C Fahey, L Corben, V Collins...
https://pubmed.ncbi.nlm.nih.gov/17056635/Martin B Delatycki, Louise A Corben
https://pubmed.ncbi.nlm.nih.gov/22752493/Larimar Therapeutics, Inc.
Lead Sponsor